Scientific Resources
Your Ardelyx Medical Science Liaison (MSL) is available for engaging in scientific exchange related to Ardelyx Medical products, disease states, and clinical practice trends.
Select Therapeutic Area:
Gastroenterology
Study Infographics
Posters and Presentations
- Safety and Tolerability of Tenapanor in Pediatric Patients With Irritable Bowel Syndrome With Constipation: An Analysis of Blinded Safety Data From a Phase 3 Study and Its Open-Label Extension (2025)
- Treatment Satisfaction With Tenapanor (IBSRELA): Real-World Survey of Patients With Irritable Bowel Syndrome With Constipation (2025)
- Treatment Satisfaction With Tenapanor (IBSRELA): Real-World Survey of Patients With Irritable Bowel Syndrome With Constipation (2025)
- Improvement in Bowel Movements Seen in Patients With End-Stage Kidney Disease and Mild to Severe Constipation After Treatment With Tenapanor (2025)
- Tenapanor Improves Abdominal Bloating Symptoms in Patients With IBS-C Experiencing Moderate to Severe Bloating (2025)
- Reduction in Gastrointestinal Visits and Portal Messaging Following Tenapanor (IBSRELA) Initiation in Patients in Community Gastrointestinal Practices (2025)
- Reduction in Gastrointestinal Visits and Portal Messaging Following Tenapanor (IBSRELA) Initiation in Patients in Community Gastrointestinal Practices (2025)
- Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Had Decreased Stool Frequency and Improved Stool Consistency (2025)
- Neither Tenapanor Nor Its Major Metabolite Were Detected in the Breast Milk of Healthy Lactating Females After 4 Days of Dosing: A Phase 1, Open-Label, Pharmacokinetic Study (2025)
- Patient-Reported IBS-C Symptom Severity Correlates Positively With Financial Burden: IBS In America 2024 Real-World Survey (2025)
- IBS In America 2024 Real-World Survey: Patients Report Differences in IBS Management, Support, and Health-Related Quality of Life Across Demographic Groups (2025)
- Patient-Reported IBS-C Symptom Severity Correlates Positively With Financial Burden: IBS In America 2024 Real-World Survey (2025)
- Efficacy of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): A Post Hoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO-1 and T3MPO-2 Studies (2024)
- Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome With Constipation in Hispanic vs Non-Hispanic Patients: A Post Hoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies (2024)
- Patients With Irritable Bowel Syndrome With Constipation From the IBS In America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation (2024)
- Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS In America 2024 Real-World Survey (2024)
- Educational needs related to irritable bowel syndrome with constipation (IBS-C) management across disciplines: a comparison of nurse practitioners, physician assistants, and physicians (2024)
- Assessment of Diarrhea in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Treated With Tenapanor: A Pooled Safety Analysis of the Phase 3 Studies (2023)
- Tenapanor Can Improve Abdominal Symptoms Independent of Changes in Bowel Movement Frequency in Adult Patients With IBS-C (2023)
- Improvement in Bloating and Overall Complete Spontaneous Bowel Movement Response With Tenapanor Treatment: A Post Hoc Analysis of the IBS-C Clinical Studies (2023)
- Evaluation of Tenapanor Efficacy in Clinical and Demographic Subgroups of Patients With Irritable Bowel Syndrome With Constipation (2023)
- Effect of Tenapanor on Treatment Satisfaction, Degree of Relief, and Quality of Life for Patients With Irritable Bowel Syndrome With Constipation (2022)
- Tenapanor Has Early Onset of Action in Treating Symptoms of Irritable Bowel Syndrome With Constipation (T3MPO-1 and T3MPO-2 Trials) (2022)
- Long Term Treatment With Tenapanor Improves Abdominal Pain and Other Abdominal Symptoms Associated With IBS-C (2022)
- Efficacy of Tenapanor in Improving IBS-C Abdominal Symptoms: A Post Hoc Analysis of Multi-item Abdominal Score From the 26-Week Phase 3 T3MPO-2 Study (2022)
- Trial in Progress: R-Ally, a Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Assess Safety and Efficacy of Tenapanor in Pediatric Patients With IBS-C (2023)
- Assessment of Diarrhea in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Treated With Tenapanor: A Pooled Safety Analysis of the Phase 3 Studies (2023)
- Management of irritable bowel syndrome with constipation (IBS-C): a nursing perspective (2023)
- Evaluation of Tenapanor Efficacy in Clinical and Demographic Subgroups of Patients With Irritable Bowel Syndrome With Constipation (2023)
- Preliminary Blinded Safety Data From R-ALLY, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tenapanor in Pediatric Patients With IBS-C (2023)
- Analysis of Patient-Reported Treatment Satisfaction and Abdominal Score in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Treated With Tenapanor (2023)
- Improvement in Bloating and Overall Complete Spontaneous Bowel Movement Response With Tenapanor Treatment: A Post Hoc Analysis of the IBS-C Clinical Studies (2023)
- Tenapanor Can Improve Abdominal Symptoms Independent of Changes in Bowel Movement Frequency in Adult Patients With IBS-C (2023)
- Long Term Treatment With Tenapanor Improves Abdominal Pain and Other Abdominal Symptoms Associated with IBS-C (2022)
- The Predictive Value of Early Response to Tenapanor for the Treatment of Hyperphosphatemia in Patients Receiving Maintenance Dialysis (2022)
- Effect of Tenapanor on Treatment Satisfaction, Degree of Relief, and Quality of Life for Patients With Irritable Bowel Syndrome With Constipation (2022)
- Efficacy of Tenapanor in Improving IBS-C Abdominal Symptoms: A Post Hoc Analysis of Multi-item Abdominal Score From the 26-Week Phase 3 T3MPO-2 Study (2022)
- Potential of Tenapanor as a Treatment for Chronic Idiopathic Constipation: A Post Hoc Analysis from the Phase 3 T3MPO-1 and T3MPO-2 Studies for Irritable Bowel Syndrome With Constipation in Adults (2022)
- Tenapanor Has Early Onset of Action in Treating Symptoms of Irritable Bowel Syndrome With Constipation (T3MPO-1 and T3MPO-2 Trials) (2022)
Nephrology
Study Infographics
Posters and Presentations
- Safety and Tolerability of Tenapanor in Pediatric Patients With Irritable Bowel Syndrome With Constipation: An Analysis of Blinded Safety Data From a Phase 3 Study and Its Open-Label Extension (2025)
- Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Had Decreased Stool Frequency and Improved Stool Consistency (2025)
- Etelcalcetide Utilization Rates Decreased and Parathyroidectomy Rates Increased Following the Incorporation of Calcimimetics Into the End-Stage Kidney Disease Bundle (2025)
- Neither Tenapanor Nor Its Major Metabolite Were Detected in the Breast Milk of Healthy Lactating Females After 4 Days of Dosing: A Phase 1, Open-Label, Pharmacokinetic Study (2025)
- Real-World Effectiveness of Tenapanor (XPHOZAH) for Treatment of Hyperphosphatemia in United States Patients on Dialysis (2025)
- Treatment Satisfaction With Tenapanor (XPHOZAH): Real-World Survey of Patients With End-Stage Renal Disease and Hyperphosphatemia (2025)
- Patient Perception of Phosphate-Lowering Treatment Regimen Improves Adherence to Therapy (2024)
- Tenapanor Treatment Added to Phosphate Binders Improved Long-Term Serum Phosphate Control as Measured by Reduction in Average Daily Phosphate Area Under the Curve (2024)
- Treatment Response to Tenapanor Categorized by Age and Comorbidities: A Post Hoc Analysis of the PHREEDOM Study (2024)
- Addition of Tenapanor and Reduction of Phosphate Binders Improved Phosphate Control Similarly in Patients Undergoing Hemodialysis and Peritoneal Dialysis (2024)
- Tenapanor Reduces Serum Phosphate With Similar Efficacy and Tolerability Profiles When Added to Various Phosphate Binders (2024)
- Sustained Phosphate Reduction Assessed by Serum Phosphate Area Under the Curve With Tenapanor Is Associated With Reduced Fibroblast Growth Factor 23 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Dialysis (2024)
- Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis With Hyperphosphatemia (2023)
- Tenapanor in Combination With Phosphate Binders Improves Short and Long-term Control of Serum Phosphate (sP) in Patients on Dialysis With Hyperphosphatemia (2023)
- An In-Depth Analysis of Serum Phosphate Changes in Patients With CKD on Dialysis: Results From the PHREEDOM Study (2023)
- Post Hoc Analyses of Serum Phosphate Changes With Tenapanor in Black/ African American and White Patients on Maintenance Dialysis (2023)
- Patient Education Improves Adherence to Tenapanor Treatment in OPTIMIZE Study (2023)
- Post Hoc Analyses of Serum Phosphate Changes With Tenapanor in Black/African American and White Patients on Maintenance Dialysis (2023)
- Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis With Hyperphosphatemia (2023)
- Tenapanor in Combination With Phosphate Binders Improves Short and Long-term Control of Serum Phosphate (sP) in Patients on Dialysis With Hyperphosphatemia (2023)
- Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Sub-Analysis of the OPTIMIZE Study (2023)
- An In-Depth Analysis of Serum Phosphate Changes in Patients With CKD on Dialysis: Results From the PHREEDOM Study (2023)
- Evaluation of Changes in Serum FGF23 With Tenapanor Treatment in Patients With Chronic Kidney Disease on Dialysis (2023)
- Reduction of Serum Phosphate With Tenapanor in Patients With Chronic Kidney Disease on Maintenance Dialysis With Severe Hyperphosphatemia (2022)
- Tenapanor Plus Phosphate Binder Reduces Interdialytic Weight Gain in Patients With Chronic Kidney Disease on Hemodialysis: Post Hoc Analysis of the AMPLIFY Study (2022)
- The True State of Hyperphosphatemia Management in Dialysis (2020)
- Interdialytic Weight Gain and Cardiovascular Disease Outcomes (2013)